Australia Continues Down OTC Path For CBD, But Will It Widen Access?
Executive Summary
[Link Fixed] Australia's Ministry of Health has provisionally switched CBD from prescription-only to OTC status to widen access in the absence of any safety concerns and to encourage companies to undertake much-needed clinical trials to prove efficacy for CBD in low doses. However, switch expert Natalie Gauld thinks these expensive trials, and therefore approved Australian OTC CBD products, may not be forthcoming.
You may also be interested in...
Industry Welcomes Australia’s OTC Drug Approach To Low-Dose CBD
Australia's Therapetics Goods Administration finalizes its decision to regulate low-dose CBD as an OTC medicine, raising the maximum daily dose to 150mg. The move is welcomed by the country's self-care industry.
If Safety Data Open Door In US, Cannabinoids’ Lawful Use In Supplements At Least A Year Off
At FDLI annual meeting, attorneys cast doubt on CBD rules outlook. Paul Joseph says regulations are at least a year away while Jonathan Havens doubts FDA is even working on regulations, including GMPs, because it is still asking industry for specific safety details.
Waiting For Cannabidiol Guidance? US FDA Reminds Industry Of ‘Many Other Requirements’
Two months after submitting CBD enforcement draft guidance for OMB review, FDA published separate draft guidance on studies for bioequivalents of an approved cannabidiol-based drug. But the draft guidance that the supplement industry awaits in pitched anticipation remains under review.